Expired activity
Please go to the PowerPak homepage and select a course.

Opioid Analgesics: Best Practices for Prescribing, Dispensing, and Preventing Diversion

This activity is for pharmacists and is sponsored by Postgraduate Healthcare Education, LLC (PHE).
There has been no commercial support for this activity.


Mark Rose, BS, MA
Licensed Psychologist and Researcher/Field of alcoholism and drug addiction
North Central Biomedical Communications, Inc
St. Paul, Minnesota


Mark Rose, BS, MA hereby states that he has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.

The following reviewer, Jeffrey Bratberg, PharmD, BCPS, hereby states the following relevant affiliations or financial relationships with a commercial interest related to the content of this activity: Receives grant/Research Support and Clinical Investigator-AHRQ, Consultant-NIDA and CDC.

Susanne Batesko, RN, BSN, Robin Carrino, L. Michael Posey, BSPharm, MA, and Jeannette Wick, RPh, MBA, FASCP, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-17-017-H03-P

Credits: 3.0 hours (0.30 ceu)
Published: February 21, 2017
Updated: February 22, 2019
Expires: February 21, 2020
Type of Activity: Knowledge
Media: Internet

Fee Information: $6.97

Estimated time to complete activity: 180 minutes


This accredited activity has been designed for pharmacists.


During the period February 21, 2017 through February 21, 2020 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


To increase pharmacists' understanding of opioid use, diversion, and abuse in West Virginia; review safe and effective opioid prescribing and dispensing practices for pain management; and review opioid antagonist prescribing and administration in West Virginia.


Upon completion of this activity, participants should be better able to:

  1. Using data from West Virginia, describe the epidemiology of chronic pain, demographics of patients who abuse opioids, addiction/abuse risk factors, and opioids' abuse potential
  2. Describe opioids' characteristics (including toxicities and drug interactions), associated use disorders, and behavioral responses to prescribed opioids
  3. Describe best practices for prescribing of opioid analgesics and management of patients with pain
  4. Discuss the complete range of legal requirements for controlled substance prescriptions, identification of fraudulent prescriptions, drug-seeking behaviors, and drug diversion
  5. Describe risk reduction approaches, including FDA risk evaluation and mitigation strategies (REMS), and the West Virginia Controlled Substance Monitoring Program
  6. Using a case study, apply best practices for opioid analgesics in ways that deal with known and potential abusers effectively, efficiently, and safely
  7. Educate patients on appropriate drug administration of naloxone rescue therapy and other overdose prevention strategies


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC.  Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.